CSI Market
Sign In | Register

Damora Therapeutics Inc (DMRA) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access DMRA Annual Cash Flow →
The quarterly cash flow data below helps track how Damora Therapeutics Inc's liquidity profile has evolved over recent quarters.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-58.96
Depreciation & amortization0.01
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation28.08
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.02
Fair Value Adjustments On Preferred Stock And Note Tranche And Derivative Obligations-
Operating Lease Right Of Use Asset Amortization Expense0.06
Issuance Of Common Stock In Connection With Vesting Of Restricted Stock Units-
Increase Decrease In Paramora Warrant Obligation4.98
Increase Decrease In Accounts Payable And Other Current Liabilities Related Parties-5.21
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable3.04
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities6.49
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.27
Other Working Capital0.02
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-21.45
Discontinued operations0.00
Net Cash flow from Operating Activities-42.47
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock325.43
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents257.62
Restricted Cash Noncurrent-
Right Of Use Asset Obtained In Exchange For Operating Lease Liability-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities325.43
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-42.47
Total Cash Flow282.96
4 historic quarters locked

Sign in to unlock the full Damora Therapeutics Inc cash flow history.

Sign In Create Free Account

About Damora Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-342307

Figures are derived from filed reports and may be restated. Historical data is subject to revision.